Mira Pharmaceuticals Announces Release of MIRA-55 Oral Formulation Update

MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc.

MIRA

0.00
  • Mira Pharmaceuticals published a press release on July 10, 2026, reporting positive preclinical results for an optimized oral formulation of MIRA-55.
  • Lead formulation showed favorable oral bioavailability, sustained systemic exposure, measurable distribution to brain and liver following oral dosing.
  • Data support continued development of MIRA-55 as a non-opioid oral candidate for chronic inflammatory pain.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607100800ACCESSWRNAPR_____1188995) on July 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.